Ulcerative colitis secondary to the use of Bevacizumab in a patient with ovarian cancer
DOI:
https://doi.org/10.54753/rsh.v1i1.2468Keywords:
Bevacizumab-associated colitis, colitis mimicking ulcerative colitis, adverse effects of bevacizumabAbstract
Gastrointestinal adverse effects of humanized monoclonal antibodies against vascular endothelial growth factor A activity are among the most common; however, there are no reported clinical cases of ulcerative colitis secondary to the use of this drug. We present the case of a 72-year-old female patient diagnosed with ovarian cancer who was receiving palliative chemotherapy with oxyplatin, cisplatin, and bevacizumab and presented with symptoms of hematochezia. Colonoscopy revealed typical findings of ulcerative colitis. Additional studies concluded that the ulcerative colitis was secondary to the use of bevacizumab. It was decided to discontinue the drug and begin treatment with mesalazine. A follow-up visit was performed 3 months after discontinuing the drug. No recurrence of symptoms was observed, and the endoscopic appearance was normal during the colonoscopy. The patient's progress was good after 18 months of follow-up. Ulcerative colitis, which causes an endoscopic appearance similar to ulcerative colitis-like inflammatory bowel disease, has a wide range of differential diagnoses, the most common being inflammatory bowel disease, ischemic causes, and infectious causes. It is important to always consider that drug-related causes of colitis may be present.References
[1] Gerriets V, Kasi A. Bevacizumab. (2023 Aug 28). In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. https://www.ncbi.nlm.nih.gov/books/NBK482126/
[2] Zhuang, H., Shi, S., Yuan, Z., & Chang, J. Y. (2019). Bevacizumab treatment for radiation brain necrosis: mechanism, efficacy and issues. Molecular Cáncer, 18(1), 21. https://doi.org/10.1186/s12943-019-0950-1
[3] Montanino, A., Manzo, A., Carillio, G., Palumbo, G., Esposito, G., Sforza, V., Costanzo, R., Sandomenico, C., Botti, G., Piccirillo, M. C., Cascetta, P., Pascarella, G., La Manna, C., Normanno, N., & Morabito, A. (2021). Angiogenesis Inhibitors in Small Cell Lung Cancer. Frontiers in oncology, 11, 655316. https://doi.org/10.3389/fonc.2021.655316
[4] Martínez, J. L., Pérez, R. M., y Gómez, T. (2020). Efectos del uso prolongado de inhibidores de la bomba de protones en la microbiota intestinal. Journal of Clinical Gastroenterology, 54(6), 541-548.
[5] Belgioia, L., Desideri, I., Errico, A., Franzese, C., Daidone, A., Marino, L., Fiore, M., Borghetti, P., Greto, D., Fiorentino, A., & AIRO Giovani Italian Association of Radiation Oncology-Young Members Working Group (2019). Safety and efficacy of combined radiotherapy, immunotherapy and targeted agents in elderly patients: A literature review. Critical reviews in oncology/hematology, 133, 163–170. https://doi.org/10.1016/j.critrevonc.2018.11.009
[6] Kaveh, S., Ebrahimi, P., Rezapour, A., Mozafari, M., & Sayehmiri, K. (2019). Bevacizumab and erlotinib versus bevacizumab for colorectal cancer treatment: systematic review and meta-analysis. International journal of clinical pharmacy, 41(1), 30–41. https://doi.org/10.1007/s11096-018-0754-1
[7] Kim, H., Shin, Y. E., Yoo, H. J., Kim, J. Y., Yoo, J. J., Kim, S. G., & Kim, Y. S. (2024). Atezolizumab-Induced Ulcerative Colitis in Patient with Hepatocellular Carcinoma: Case Report and Literature Review. Medicina (Kaunas, Lithuania), 60(9), 1422. https://doi.org/10.3390/medicina60091422
[8] Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T. Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., Li, D., Verret, W., Xu, D. Z., Hernandez, S., Liu, J., Huang, C., Mulla, S., Wang, Y., Lim, H. Y., Zhu, A. X., … IMbrave150 Investigators (2020). Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. The New England journal of medicine, 382(20), 1894–1905. https://doi.org/10.1056/NEJMoa1915745
[9] Feuerstadt P., y Brandt L., (2021). Sleisenger y Fordtran: Enfermedades digestivas y hepáticas (11ava ed.). Barcelona, España. Elsevier
[10] Gilaad G y Siew C., (2021). Sleisenger y Fordtran: Enfermedades digestivas y hepáticas (11ava ed.). Barcelona, España. Elsevier
